TREACE MEDICAL CONCEPTS INC
TMCINASDAQTrading Snapshot
- Day Range
- $4.90 โ $5.24
- 52-Week Range
- $1.17 โ $6.91
- Volume (shares)
- 368,086
- Avg Volume (shares)
- โ
- Shares Outstanding
- 65.0M
- Next Earnings
- 2026-11-06
Fundamentals Snapshot
- Annual Revenue
- $213M
- Last Q Revenue
- $45M
- P/E Ratio
- -5.2
- P/S Ratio
- 1.5x
- EPS (TTM)
- $-0.91
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +2.4%
TREACE MEDICAL CONCEPTS INC
TMCIAbout TREACE MEDICAL CONCEPTS INC
Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty System, enables surgeons to correct all three dimensions of the bunion deformity, stabilize the first TMT joint, and allow return to weight-bearing in a walking boot; minimally invasive products for four bunion classes; Nanoplasty 3D Minimally Invasive Bunion Correction System delivers a reproducible 3D correction of the bunion deformity through a cosmetically appealing; and Percuplasty Percutaneous 3D Bunion Correction System that provides 3D correction of the bunion deformity through percutaneous incisions. It also provides Adductoplasty System, a system designed for the correction of metatarsus adductus deformities and osteoarthritis of the midfoot; SpeedMTP Rapid Compression Implant; SpeedPlate Implant Fixation Platform to address the fusion of larger bones of the midfoot and rearfoot; SpeedPlate Micro-Quad implant, an implant designed for stability and fit in small incision surgical approaches; and SpeedAkin Anatomic Compression Implant. In addition, the company offers The IntelliGuide patient specific instrumentation provides patient-specific, 3D-printed cut guides, and a pre-operative plan for a complete picture of the deformity and correction. Further, it provides FastGrafter Autografter Harvesting System; SpeedRelease Guided Release Instrument; TriTome Triple-Edge Release Instrument; RazorTome 7mm Precision Osteotome; LapiTome Hooked Bone Removal Osteotome; GreatRelease Rapid MTP Release Instrument; CornerChisel Release Tool; NanoRasp MIS Bone Contouring Tool; FeatherRasp Rapid Bone Contouring Instrument; and Akinator Single-cut Akin Wedge Osteotomy tool. Additionally, the company offers biologics and wedges, such as Treace Allograft Wedges; and CortiFuse Flowable Cortical Fibers. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida.
Otter Score Breakdown
How it's scoredFive components, each rated 1โ5โ and equally weighted (20%), averaged to a 0โ100 score:๐ Quality โ gross margin๐ Growth โ revenue YoYโ๏ธ Valuation โ P/S ratioโก Momentum โ 30-day price change๐ง Dilution โ 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
Analyst Ratings
โLatest News & Updates

Treace to Report Third Quarter 2026 Financial Results on November 6, 2026
PONTE VEDRA, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (โTreaceโ or the โCompanyโ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunio

Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?
Did Treace Medical Concepts, Inc. Insiders Breach their Fiduciary Duties to Shareholders?PR NewswireNEW YORK, Sept. 26, 2026Shareholders are encouraged to conta

Treace Announces Results of Three Clinical Studies Including the Milestone 5-Year ALIGN3Dยฎ Study Demonstrating Sustained, Positive Outcomes of the Lapiplastyยฎ Procedure
PONTE VEDRA, Fla., Sept. 17, 2026 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (โTreaceโ or the โCompanyโ) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of buni

Treace Highlights Product Innovations and Clinical Data Across its Expanding Foot & Ankle Portfolio at the 2026 AOFAS Annual Meeting
New product offerings extend bunion market leadership and accelerate penetration into new foot & ankle market adjacencies New product offerings extend bunion market leadership and accelerate penetration into new foot & a

Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript
Treace Medical Concepts, Inc. (TMCI) Q2 2026 Earnings Call Transcript

Treace Medical Concepts Q2 Earnings Call Highlights
Treace Medical Concepts NASDAQ: TMCI reported second-quarter 2026 revenue of $45.4 million, down 4% from the prior-year period, as lower procedure-kit sales to stocking distributors and a continued shift toward lower-pri